Thymogen Research Overview (also known as Glu-Trp dipeptide, EW dipeptide, Thymogen immunomodulator)
A dipeptide studied for immune restoration following infection, normalization of post-infection inflammatory cycles, and systemic immune resilience support. Research interest includes post-illness recovery models. Often combined with Thymalin and Vladonix in immune recovery research.
What Is Thymogen?
Thymogen is a synthetic dipeptide bioregulator with the sequence Glu‑Trp (EW), originally isolated as one of the active short peptides within the thymus extract Thymalin and later synthesized as a defined molecule. As one of the smallest effective thymic peptides, it retains a potent immunomodulatory profile despite its minimal size, and has been approved for clinical use in Russia for immune deficiency conditions associated with aging, chemotherapy, and chronic infections.
Important distinction: Thymogen (EW dipeptide) is different from Thymogen Alpha‑1 (an oral combination supplement pairing Thymogen with Lys‑Glu) and from Thymosin α1 (Thymalfasin, a 28-amino acid drug for hepatitis B). In Western markets, Thymogen EW is available only as a research chemical or supplement.
Key Benefits
- Normalizes T/B lymphocyte ratios in immunodeficient states
- Stimulates IL-2 production and NK cell cytotoxicity
- Enhances macrophage phagocytic activity
- Supports hematopoiesis and post-trauma regeneration
- Bidirectional immune modulation — activates without overstimulation
Mechanism of Action
Thymogen activates thymic epithelial cell signaling pathways that promote T-lymphocyte maturation and differentiation. Khavinson's group describes short peptides like Thymogen as interacting directly with complementary DNA promoter sequences to regulate gene expression for cytokines, heat-shock proteins, fibrinolysis, and cell differentiation — effectively functioning as an epigenetic regulator of thymic immune programs.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Timing | AM or PM, consistent daily timing |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Lyophilized: 2–8°C; Reconstituted: use within 30 days at 2–8°C; protect from light |
Research Indications
ImmunitySupported Research
Secondary ImmunodeficiencyPrevention and complex treatment of acute and chronic viral and bacterial diseases of the upper respiratory tract. Prevention of immune suppression in post-traumatic and postoperative periods. Experimental candidiasis: Thymogen injections attenuated disease severity by activating the thymic-dependent immune system.
RecoveryPreliminary Data
Hematopoiesis & Post-Treatment RecoveryNormalization of hematopoiesis and regeneration following chemo-radiotherapy, surgical trauma, or cytotoxic therapies. Restored T/B lymphocyte counts and improved phagocytic activity documented in Thymalin/Thymogen literature.
Anti-AgingPreclinical Only
Age-Related Immune DeclineExploration of Thymogen as a small-molecule immune modulator for aging-related immune exhaustion. Modern RUO and integrative protocols combine with other Khavinson bioregulators (Vilon, Crystagen). Western placebo-controlled trial data absent.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General immune support (RUO) | 0.5–2 mg | Once daily | SubQ / IM |
| Post-infection / recovery support | 0.5–2 mg | Once daily | SubQ / IM |
| Thymogen Alpha-1 oral support | 250–500 mcg | Once daily | Oral (capsule) |
Cycle Note
Courses are typically 10–20 days, with breaks of 1–3 months before repeating — consistent with other Khavinson bioregulators. Effects on immune balance and hematopoiesis may persist weeks beyond the dosing period due to gene-expression modulation.
Peptide Interactions
Thymogen is one of the active short peptides within Thymalin; mechanisms and clinical indications overlap significantly. Using both simultaneously may produce redundant rather than additive effects.
Thymogen Alpha-1 (Thymogen + Lys-Glu) is marketed as a small-peptide alternative to Thymosin α1. Evidence for equivalence is early and not independent; Thymosin α1 has substantially more clinical trial data.
These short Khavinson immune peptides activate differentiation, viability, and reduce apoptosis in immune cell subpopulations. Often used as multi-peptide immune stacks in functional/longevity protocols.
Legacy use of Thymogen involved co-administration with standard antiviral therapies and vaccines to boost immune correction. Adjunctive role; formal pharmacokinetic interaction data limited.
Reported Research Timeline
01During the active course (5–10 days) (reported in cited studies): Thymogen's Glu-Trp dipeptide interacts with thymic epithelial cells and T-lymphocyte populations, initiating upregulation of IL-2 and normalization of T-cell proliferation. Early effects on CD4/CD8 ratios and NK cell activity begin during this phase but are not subjectively perceptible.
02Weeks 1–4 post-course (reported in cited studies): Immune parameters shift measurably — lymphocyte populations normalize, infection susceptibility decreases, and inflammatory cytokine balance improves. RUO practitioners report reduced frequency of minor infections and faster recovery in the weeks following a Thymogen course, consistent with the immune restoration mechanism.
03Months 1–3 (sustained immune effects) (reported in cited studies): The immune normalization established during and after the course is maintained. Khavinson research data describe improved B- and T-cell balance, enhanced natural killer activity, and better responses to immune challenges. These effects support the 3–6 month repeat interval used in geroprotective protocols.
04Long-term (repeat courses) (reported in cited studies): Chronic course-based administration (every 3–6 months) in Khavinson longevity studies contributed to reduced tumor incidence and improved immune parameters in aging animal cohorts. Human geroprotective protocols extrapolate this finding, using Thymogen as a maintenance immunomodulator. Data in humans is predominantly Russian and non-randomized.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Thymalin and Thymogen are reported to have practically no side effects in legacy clinical and experimental literature, with broad use across diverse conditions and no significant toxicity at recommended doses.
Experimental studies did not report immunosuppressive or overt adverse effects; Thymogen acts as a bidirectional modulator, not a blunt stimulant.
No large, independent, placebo-controlled Western trials exist to confirm infection resistance or immune marker improvements in modern cohorts.
Not FDA-approved; not approved in the EU or UK. Sold only as a research chemical or supplement labeled "not for human consumption" in many jurisdictions.
Not recommended during pregnancy or breastfeeding — no safety data in these populations.
Distinct from Thymosin α1 and Thymosin β4 — confirm product identity (Glu-Trp EW dipeptide) before use.
Stop Use and Seek Medical Attention If:
Unexpected worsening of infection or immune symptoms during use
Allergic reactions — rash, hives, difficulty breathing, injection-site swelling
Any systemic symptoms not present before starting: fever, lymphadenopathy, fatigue
Consult a qualified healthcare professional before use, especially with existing immune conditions
Quality Indicators
Verified Marker
Peptide Identity Confirmed (MS)
Glu-Trp (EW) sequence confirmed by mass spectrometry (MS). Reputable RUO suppliers provide a Certificate of Analysis with MS confirmation and HPLC purity (≥98%).
Verified Marker
Correctly Labeled RUO Vials
RUO vials clearly labeled "Thymogen (EW)" or "Glu-Trp dipeptide," 20 mg, with recommended reconstitution volume (5 mL). Oral Thymogen Alpha-1 capsules list 250 mcg Thymogen per capsule.
Verified Marker
Proper Storage Maintained
Lyophilized vials stored refrigerated or frozen (per vendor spec), protected from light. Oral capsules stored cool and dry with clear expiration dates and batch numbers.
Acceptable Range
Short Shelf Life After Reconstitution
Compounded and RUO preparations typically have shorter stability than commercial products. Use within vendor-specified window (typically 14–28 days refrigerated); verify expiration dates.
Quality Concern
Confusion with Thymosin α1 or β4
Products conflating Thymogen (EW dipeptide) with Thymosin α1 (28-aa drug) or Thymosin β4 are mislabeled. These are entirely different compounds with different mechanisms and safety profiles.
Quality Concern
No Certificate of Analysis / CoA
Inadequate disclosure of peptide content, purity, or identity. No CoA, or "immune booster" marketing without clear research chemical distinction, are red flags for counterfeit or adulterated product.
Research Citations
- The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
Deigin V, Linkova N, Vinogradova J, 2024, Int J Mol Sci - Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VK, 2022, Int J Mol Sci - Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity
Deigin V, Ksenofontova O, Khrushchev A, 2016, ChemMedChem - [Influence of peptides from pineal gland on thymus function at aging]
Lin'kova NS, Poliakova VO, Trofimov AV, 2010, Adv Gerontol - Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides
Deigin V, Ksenofontova O, Yatskin O, 2020, Int Immunopharmacol
"
"
Research Focus
Immune regulation, T-cell support, Anti-aging, Infection resistance, Thymic peptide
Verified Vendors Carrying Thymogen
Frequently Asked Questions
What should researchers watch for with Thymogen?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Thymogen?
During the active course (5–10 days) (reported in cited studies): Thymogen's Glu-Trp dipeptide interacts with thymic epithelial cells and T-lymphocyte populations, initiating upregulation of IL-2 and normalization of T-cell proliferation. Early effects on CD4/CD8 ratios and NK cell activity begin during this phase but are not subjectively perceptible.
How is Thymogen typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →